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Abstract 
The internet provides a growing medium for the emergence of psychoactive 
substances, with very little information pertaining to the safety of their use. It is 
imperative that these Emerging Psychoactive Substances, (EPS), are monitored, in 
order to detect new substances, and thus allow for researchers and clinicians to 
prepare for the effects of these substances on the general population. The current 
research aimed to implement a pilot internet monitoring system to replicate the 
Psychonaut Web Mapping Project in Europe. From this pilot data, the second aim 
was to provide a narrative review of the top ten identified EPS available to 
Australian markets. The study implemented a 12 month internet monitoring system 
and identified 43 online stores providing EPS to Australia, with a total of 212 total 
products identified as available to Australian consumers. The top ten most common 
EPS identified using the pilot monitoring system were: MDAI, 5-IAI, 
Methiopropamine, 5-MeO-DALT, 4-FMC, 4-MEC, MDPV, Butylone, DMAA, and 
Methylene. These substances were then researched on user forums to provide greater 
information on subjective user experiences, with a focus on physical or 
psychological harm and potential for substance abuse and dependence. MDPV was 
most frequently associated with harm in user reports, in addition to being identified 
as potentially addictive. This finding has been verified in the research literature more 
generally. The current findings indicate that there is a need to monitor the ever 
changing internet market in order to have some knowledge of the new substances 
that may be consumed by individuals in Australia. Furthermore, there is a need for 
more research and available information, in order to provide recreational users with 
evidence-based information. The potential for psychological harm has been verified, 
with a particularly concerning trend toward newly identified substances of abuse. 
There is a growing need to provide health care workers, and governing bodies, with 
information pertaining to the effects of these drugs, and their potential for abuse. 
The use of psychoactive substances in human populations has occurred and been 
documented from very early on in human history. From the spiritual use of 
hallucinogenic substances, to the more recent use of psychoactive substances to 
induce recreational euphoria, energy, and other desirable effects. The consumption of 
traditional psychoactive substances, ones that have well known properties, such as 
ecstasy, methamphetamine, and cannabinoids, is evolving into a market of less well 
known substances (EMCDDA, 2012). In the literature to date, these substances, 
which can produce stimulant, entactogenic, psychedelic and cannabinomimetic 
effects, are becoming more prevalent. One of the key research bodies in Australia, 
The Ecstasy and Related Drugs Reporting System, (EDRS), who investigate 
substance use with ecstasy and other psychostimulant users, refer to these new 
chemical products as Emerging Psychoactive Substances, or EPS, (EMCDDA, 
2012). Researchers in the United Kingdom use the term Novel Psychoactive 
Substances (NPS). In Australia, EPS have been identified as being used by regular 
ecstasy users (N=693), with a small percentage of the interviewed sample reporting 
use of psychedelic phenethy !amines, ( 1-2% ), psychedelic tryptamines ( < 1 % ), and 
Stimulant EPS (16%) (Sindicich & Bums, 2011). 
Currently, the rate of discovery for EPS is astounding, with the EMCDDA (2012) 
reporting 170 new online drug shops in 2010, increasing to 693 in 2012. Seven of the 
top ten most prevalent drugs identified by the EMCDDA were EPS. Due to the 
nature of illicit recreational substance use in society, chemical producers are looking 
to capitalise on the production of newer, more elaborate/complex psychoactive 
substances, in order to import and distribute them in countries where the law is 
unable to keep up with an ever expanding market (EMCDDA). 
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EPS can be sold in traditional stores or, on the internet by typically untraceable 
online producers and distributors (Psychonaut Web Mapping Project, 2010; 2012; 
EMCDDA, 2012, Measham, Moore, Newcombe & Welch, 2010). As such, the easily 
accessible nature of these substances incites a question into the nature of these 
chemicals, and the possible effects that they may have on unsuspecting populations. 
As previously mentioned, because these substances are often produced very rapidly, 
or by companies which do not intend them to be used recreationally, there is little to 
no testing on the effects of said substances in human populations. Often, consumers 
test these drugs for the first time, with little to no knowledge of the potential 
psychoactive effects, or their long term consequences. Within the online community, 
some recreational drug users have come to produce their own online database, 
cataloguing the effects of these new substances. These users have been termed 
'psychonauts' and have been known to post on online forums, such as Pillsreports, 
Bluelight.ru and Erowid.org (Psychonaut Web Mapping Project, 2010; 2012). These 
psychonauts play a valuable role in providing other users with information about the 
physical and psychological effects of these substances. Despite the existence of 
online users, who are willing to risk their health in order to provide other users with a 
database cataloguing the effects of EPS, it remains of utmost importance that these 
EPS are both monitored, and tested, and that this information is dispersed to both the 
research and wider population. 
In Europe, the emergence of new psychoactive substances has been monitored 
since 2006 (Psychonaut Web Mapping Project, 2010; 2012, EMCDDA, 2012). This 
is in order to both create a database of, and monitor the prevalence and use of these 
substances, and to also investigate and create a means to access all of the information 
available to researchers in regards to the chemical properties, psychological, and 
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physical effects of these substances in human populations. Additionally, these 
monitoring systems are able to provide an early warning system for EPS that may be 
particularly problematic. In Europe, the findings of the RedNet project, now known 
as the European Psychonaut Web Mapping Project is alarming. There has been an 
exponential rise in the number of vendors who are selling to European countries. In 
January 2010 alone, there were 170 online vendors to purchase EPS. In 2012, this 
number had risen to 693. The rise in the sheer number of these vendors has 
implications for the availability and dispersion of these substances throughout 
Europe. Despite data being available on European markets, it is questionable how 
generalisable such research is to an Australian context (Psychonaut Web Mapping 
Project, EMCDDA). 
First and foremost, some European vendors will not supply to countries other than 
the EU, and secondly, the internet sites that do appear to Australian markets may 
supply different types ofEPS. Thus the range of products and relative availability of 
these products may differ substantially when looking at Australian relevant markets. 
In New Zealand, the existence of a prominent legal high market may imply that 
Australian markets are subject to a different range or variety of EPS, than those 
available to European or American markets (Wilkins & Sweetsur, 2010). Due to the 
possibility of these differences, there is a need to investigate and determine the 
availability of EPS to Australian consumers. 
The EPS that have been discovered, and anecdotally recorded, have been linked to 
significant harm (Borek & Holstege, 2012; Durham, 2011; Murray, Murphy & 
Beuhler, 2012; Rosenbaum, Carreiro, & Babu, 2012; Ross, Watson & Goldberger, 
2011; Sanders, Lankenau, Jackson Bloom & Hathazi, 2008; Thornton, Gerona, & 
Tomaszewski, 2012). In some instances, the labelling provided by manufacturers is 
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misleading or inaccurate, leading to misinformed consumers who are purchasing 
substances with unknown chemical contents. These EPS are sometimes sold as 'legal 
highs', 'research chemicals', or 'bath salts', in order to reduce the level of suspicion 
that may be raised by regulatory bodies. Furthermore, the addition of the proviso of 
sold 'not for human consumption', adds to the surreptitious sale of these products to 
recreational users. The main issue of misleading labelling or selling EPS as 'not for 
human consumption' lies twofold: the regulatory bodies may not realise the intended 
purpose of such products, (i.e. for recreational use), and users of these products may 
be consuming an unknown substance at an unknown level, resulting in a greater 
severity of physical or psychological harm. This harm may be initial, such as 
poisoning, temporary episodes of psychosis, or memory lapses/loss of control, or 
may be in the form of long term psychological abuse and dependence (Baumann, et 
al., 2012; Bloomer, Innocence, Farney, Bell & Canale, 2011; Watterson et al., 2012). 
There is evidence of both short and long term negative outcomes as a result of 
recreational use of EPSThese substances are emerging so rapidly that systematic 
study of long term effects is difficult. One substance that has become prevalent in 
use, and thus provides some insight into both short and long term harm, is 
Mephedrone. 
Mephedrone (4-methylmethcathinone, 4-methylephedrone Stimulant (S) & 
Entactogen (E)), became a known substance in 1929, and began to be distributed in 
2004 by a website called Neorganics. In 2008 it was reportedly present in Australia. 
In 2010 it was banned in the United Kingdom, however it was still being sold by 
dealers in late 2010 (Winstock & Marsden, 2010). The precursors for the production 
of Mephedrone, when it originally emerged, were more easily obtained than MDMA, 
thus adding to its rapid production, consumption, and wide availability. It is usually 
sold as a white powder (which can vary from a crystalline white to yellow 
colouration). The chemical is soluble and has been described to have an unpleasant 
odour. Mephedrone has also been sold in capsule and tab form, and has been 
reportedly sold under the guise of ecstasy tablets. Users administer the drug through 
a variety of means, most often through snorting, although it is also administered 
through bombing, and shelving/shafting (Matthews & Bruno, 2010; Measham, 
Moore, Newcomb & Welch, 2010; Schifano et al., 2011; Winstock & Marsden). 
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Winstock and Marsden (2010) have documented the acute subjective effects of 
mephedrone on users by using telephone interviews and testing urine samples. They 
found that users reported both positive and negative physical and psychological 
effects. The positive effects included euphoria, stimulation, elevated mood, lessened 
aggression, heightened sexual arousal, improvements in mental functioning, and 
heightened appreciation for music. The reported negative effects were: loss of 
concentration, reduced visual focus, memory deficits, reduced 
awareness/consciousness, strange behaviour, agitation, and loss of sleep. Most 
disturbing of the negative effects were anxiety, hallucinations, and delusions, which 
were mostly associated with prolonged use, or high dose levels, in addition to use 
with other substances such as alcohol, ketamine, GHB, and other psychostimulants. 
If evidence was present of long term injecting administration, these effects were 
particularly prominent. A noteworthy exception to negative effects of mephedrone 
was that aggression was reportedly less common when compared to cocaine 
(Winstock & Marsden). 
Mephedrone has been reported to produce both withdrawal and comedown 
effects. These include increased appetite, stuffy nose, tiredness or fatigue, unusual 
body odour, anxiety, depression, emotionality /tearfulness, irritability, inability to 
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concentrate, loss of memory, and urges or cravings to re-administer (Matthews & 
Bruno, 2010; Measham, Moore, Newcomb & Welch, 2010; Schifano et al., 2011; 
Winstock & Marsden, 2010). In terms of negative psychological outcomes, including 
abuse and addiction, the existence of symptoms such as urges to take more of the 
drug, and feeling anxious or depressed as the drug wears off, are troubling. Although 
mephedrone provides only one example of an EPS, the implications of substances 
being widely dispersed among the population, which are not regulated or tested, and 
have the potential to lead to addiction or contribute to the onset of other 
psychological disorders, is concerning. 
In terms of dependence specific symptoms, Winstock and Marsden (2010) found 
that users developed cravings for mephedrone, used for longer periods of time, or in 
greater amounts than what they had intended, and were concerned about their use. 
Furthermore, users reported tolerance to the effects of mephedrone. Additionally, the 
users of mephedrone reported that their motivation to use the substance was highly 
influenced by its legality, (though this was not reported for mephedrone specifically), 
and its distribution through online sources. This raises the issue of the rapidly rising 
number of EPS, and heightens the link between the legality of the substance, and its 
availability online, and the motivation for recreational users to purchase such 
substances (Bruno et al., 2012; Psychonaut Web Mapping Project, 2010; 2012; 
Schifano et al., 2011; Winstock & Marsden, 2010). 
Mephedrone use, along with other EPS, has been reported in Australia. The EDRS 
(2010) found that frequent ecstasy users (n=l63) reported consuming a range of 
psychedelic phenethylamines along with psychedelic tryptamines and stimulants, 
such as mephedrone. Of the 21 % of frequent ecstasy users who reported using 
mephedrone, 30% reported only using it once. Other EPS, such as 
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methylenedioxypyrovalerone (MDPV) and methylone have been identified in 
chemical analyses of wastewater in urban areas and at other venues, such as music 
festivals (Chen et al., 2012), while local media have reported harms associated with 
EPS use (Chamberlin, 2012; Olding, 2012). Bruno and colleagues (2012) found that 
among regular ecstasy users (REU), use ofEPS was evident in over 25% of those 
surveyed. This use was limited to predominantly mephedrone (stimulant), as opposed 
to psychedelics (reportedly used by 13% of those surveyed). Mephedrone was most 
commonly used in Tasmania (47%) and Victoria (28%) and was found to be 
associated with harms such as risky behaviour. 
Aims 
The aim of the current project was to implement a pilot web monitoring system, 
using the methodologies of the Psychonaut Web Mapping Project. The purpose of 
this was to determine the existence of websites that readily supplied EPS to 
Australia, in order to monitor their products. In addition to monitoring, and the 
identification of both vendors and substances being sold, the second aim was to 
research and catalogue detailed information about the chemical nature of the 
substances being sold. For each prevalent EPS, user forums were investigated, in 
order to record qualitative information about the potential psychological effects of 
these chemicals on both one off, and regular EPS users. This information was then 
collated, in order to provide structured summaries of EPSs, including their 
availablility,, and reported psychological and physical effects 
Method 
Study 1 
Design 
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Study 1 involved the implementation of a pilot internet monitoring system in 
Australia. Quantitative analysis was used to determine the magnitude of monthly 
searches for EPS within Australia, the number of stores selling EPS to Australia, the 
six month survival rates of stores, the stimulant, entactogen and psychedelic 'blends' 
available to Australian consumers, and the stimulant, entactogen, psychedelic, and 
dissociative products available to Australian consumers. The study aimed to 
discover the top ten most frequently advertised for sale substances available within 
online websites. 
Apparatus 
To determine the magnitude of online searches for EPS within Australia, the 
Google Adwords tool was used on a monthly basis. This tool was able to provide 
data on the number of local monthly searches for the key terms used in the study. A 
computer and internet, with specific search tools - Google, Yahoo, and Bing were 
used, as the search tools to uncover the website vendors supplying EPS to the 
Australian market. 
Procedure 
Via reproduction of the methodology employed by the European Psychonaut Web 
Mapping Project, a standardised set of search terms was produced. These included, 
('legal high' OR 'herbal high' OR 'smart drug' OR 'research chemical" OR 'bath 
salt' OR 'plant food' OR 'party powder' OR 'party pill' OR 'ethnobotanical'). These 
terms were entered into the top Australian search engines, which were, according to 
Alexa.com: Google.com.au, Yahoo.com, and Bing.com using default settings. 
Searches were made on one day per month, within a 7 day period from the 15th day 
of the month. This involved searches, which were terminated following 100 
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sequential search returns where no EPS retailer was identified. Internet retailers that 
were identified as selling stimulant or psychedelic EPS to Australia were then 
monitored, which included documentation of the available stock, and ongoing 
monthly inclusion in monitoring. During each search, the continued activity of these 
websites was confirmed, and their current stock was updated. If the website was 
found to be inactive or no longer providing to Australia, they were removed from the 
list of active websites. The prevalence of monthly web searchers from Australia was 
estimated using the Google Adword's tool. 
Results 
Study 1 
The internet monitoring pilot found a total of 43 internet vendors providing 
EPS to Australia (see Figure 1), 37 of which were no longer monitored due to 
inactivity or no longer selling EPS to Australia . In a six month period, the survival 
rate of each identified vendor was markedly reduced, (see Figure 2). The internet 
monitoring system identified a total of212 new products to Australian markets over 
a 12 month period, with an average of 10 new products identified each month (see 
Figure 3). These products were identified as having stimulant, entactogenic, 
psychedelic and dissociative chemical ingredients. These results suggest that the 
Australian public is able to purchase from a variety of online vendors, and that these 
vendors do in fact supply substances with varying degrees of psychoactive 
properties. These vendors do not appear to last long, with only 57% of stores 
remaining at a 6 month follow up period. 
Figure 1 
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Figure 1. Stores selling to Australia by month. Lighter grey areas indicate 
new stores identified in the month. 
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Figure 2. Percentage of online vendors remaining after a 6 month period of 
internet monitoring. 
Figure 3 
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Figure 3. Number of available products, categorised by effect 
(psychedelic/dissociative versus stimulant/entactogen) over each month in 
Australia. 
Preliminary Discussion 
Internet searches within Australia indicate an interest in EPS by Australian 
consumers. There are limited retailers selling EPS to Australian consumers in 
11 
comparison to the European market (Psychonaut Web Mapping Project, 2010; 2012). 
The pilot internet monitoring system has identified that there are a variety of 
substances being made available to Australian consumers, with a total of 212 
'blends' ( chemical contents unspecified), and 86 specified chemicals, identified 
during the 12 months of monitoring. 
The evidence suggests that these products are not simply harmless every-day 
substances, under the guise of clever product marketing; rather, they do appear to 
contain psychoactive chemicals. The evidence from US analyses of 'blends' has 
confirmed the presence of chemical substances, such as MDPV, methylone and 
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mephedrone, either as a singular chemical substance, or in varying combinations 
(Spiller, Ryan, Weston & Jansen, 2011). Purchased 'blends' have been found to 
contain MDPV (Murphy, Dulaney, Beuhler & Kacinko, 2012; Murray et al., 2012; 
Spiller, Ryan, Weston & Jansen). Reports from the U.S. have indicated adverse 
health effects to users of stimulant 'blends'. This could be due to either the substance 
itself causing harm, or the unknown information pertaining to the nature of the 
substances being consumed, leading to use above and beyond what consumers would 
initially consider 'safe doses'. This is in addition to the many instances of substances, 
identified to have chemical contents with psychoactive properties, being directly 
found to have negative physical and psychological effects (Dorairaj, Healy, 
McMenamin & Eadie, 2012; Gee, Jerram & Bowie, 2010; James et al., 2011; 
Johnson, Conarty & Nichols, 1991; Schifano, Corkery & Ghodse, 2012). 
MDPV has frequently been associated with sympathetic effects, such as 
tachycardia, hypertension, hyperthermia, and seizures. Psychological effects 
reportedly found are panic attacks, agitation, paranoia, and hallucinations (Ross, 
Watson & Goldberger, 2011). A case study of MDPV found that a 23-year-old male 
was admitted to the Emergency Department, experiencing 'bizarre behaviour', 
suicidal thoughts, and hallucinations (Thornton, Gerona & Tomaszewski, 2012). An 
instance of MDPV use in the USA resulted in one user developing agitated and 
aggressive behaviour, resulting in cardiac arrest (Murray, Murphy & Beuhler, 2012). 
Other instances of hyperthermia, organ failure, paranoid psychosis and seizures have 
also been identified (Borek & Holstege, 2012; Durham, 2011). Further to these 
psychological harms, the addictive and reinforcing properties of MDPV specifically 
are beginning to be more widely researched (Baumann et al., 2012; Watterson et al., 
2012). 
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The monitoring system's ability to discern specific chemicals available to 
Australian markets is hindered by the rate at which retailers and products become no 
longer available to consumers. This may result in some difficulty for consumers in 
keeping up with information, and reporting adverse effects that they have been 
experiencing from the use of these substances. Furthermore, health agencies may be 
unable to track and create appropriate harm minimisation strategies, or provide 
sufficient information to the public and consumers. In addition to this, health care 
providers, in particular, clinical psychologists, or law enforcement agents may not be 
aware of the effects of such substances, with their increasing use and changing nature 
very difficult to both identify and follow over time. The very nature of internet sales 
of EPS is intended to outpace the legal restrictions posed by different countries and 
agencies. Thus, the rapid development of EPS is likely to result in a greater number 
of users who are not aware of the potential harms associated with the use of new 
chemicals, which have not been tested or well documented (Chamberlin, 2012; 
Olding, 2012; Murphy, Dulaney, Beuhler & Kacinko, 2012; Murray et al., 2012; 
Schifano, Corkery & Ghodse, 2012). 
The main limitation of the current study is that it did not take into account the 
change in market dynamics. This would require an evaluation and updating of the 
search terms used during the monthly internet search. Due to the change in market 
advertising and availability of products, the search terms that were originally defined 
may not have encompassed the changing variety of retailers and products available to 
internet consumers. Furthermore, the internet monitoring system does not provide a 
complete or global picture of the range of retailers and products available to 
Australian consumers. The internet monitoring system was not able to capture new 
EPS that were reported by the media as being available in shopfronts (Olding, 2012). 
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This implies that new EPS can become available to consumers without being picked 
up by internet monitoring systems. Further to this, the harms associated with these 
unrecorded EPS become another unknown (to the public, researchers, and 
consumers). Thus, future research must include some element ofrecording oflocal 
non-internet retailers, and other non search identified internet retailers in order to 
capture the full range of retailers and products available to Australian markets. 
Another limitation is that the study excluded products or websites which were 
selling only synthetic cannabinoids. It was decided, due to other researchers 
undertaking similar data monitoring for this specific substance class, that the current 
study would focus primarily on EPS with psychoactive and psychedelic properties 
only. 
Study 2 
Method 
Design 
Study 2 employed a qualitative analysis of the available information 
pertaining to the top ten most prevalent drugs available to Australian consumers. For 
the identified drugs, user forums were investigated, and user reports compiled to 
provide a narrative review of the chemical structure, nature, psychological and health 
effects of each drug on users. The study used Erowid.org, PillsReports and 
Bluelight.ru to find the information required to document the perceived effect of the 
drug, with a specific focus paid to psychological harm, dependence, and evidence of 
substance abuse potential. Based on the classification of narratives as relevant to the 
presence of either psychological or physical harms, as reported by the user, examples of 
such harms were compiled in order to describe the reported effects on the user .. 
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Participants 
Participants included individuals who had used the top ten drugs, and posted 
user reports on user forums, found on the internet. 
Apparatus 
The main internet user forums used to compile user reports were Erowid, 
PillsReports, and Bluelight.ru. It was decided that these sites were accurately 
representative of reports from individuals who test EPS, with substance users on 
these sites employing a relatively scientific and systematic approach to the 
dissemination of their experiences. Implied consent was assumed for user reports, 
given that these websites are accessible to the public, with thread posters aware that 
their information is presented to a public forum. 
Procedure 
As stated previously, the top ten drugs identified by the internet monitoring 
pilot were used as a guide to identify specific and potentially prevalent drugs, in 
order to investigate the experiences of users on user forums. Each drug was entered 
into the user forum search tool, and the articles posted by users were examined. The 
specific focus of study 2 was to identify evidence from user reports of harms, in 
particular psychological harms, with a specific focus on evidence of substance abuse 
or dependence. User reports were then combined to form a narrative review of the 
chemical structure of the identified substance, in addition to the user reports detailing 
psychological effects, and evidence of harm, (either physical or psychological). In 
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total, 69 user reports were reviewed, (9 for 4-MEC, 8 for 5-MeO-DALT, 7 for 
Butylone, 8 for MDAI, 23 for MDPV, 8 for Methylone, 2 for Methiopropamine, 2 
for 5-IAI, and 2 for Flephedrone). All information provided by users was reported in 
the narrative reviews. 
MDAI 
<o 
0 
5-/AI 
Results 
a. Effects classifications: empathogen; entactogen 
b. Chemical name: 5,6-methylenedioxy-2-aminoindane 
c. Description: synthetic chemical- first available in 2009 (online)-
comparable effects to MDMA (ecstasy), although reported weaker 
effect and lower stimulation. 
d. User reported psychological and physiological effects: euphoria, 
drowsiness, physical warmth, increased affection, enhanced hearing 
(music), clearer thoughts, faster reflexes, sensitivity to light and 
sound, increased talkativeness, and jaw tension. 
e. Evidence of harm from user reports: 'slight anxiety'. 
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a. Effects classification: entactogen - 'releasing agent of serotonin, 
norepinephrine and dopamine' - monoamine release agent. 
b. Chemical Name: 5-Iodo-2-aminoindane 
c. Description: Substitute for MDMA - analogue to amphetamine - known to 
cause some serotonergic neurotoxicity. 
d. User reported psychological and physiological effects: Bluelight.ru (no 
information available on Erowid.org): decrease in body temperature, strange 
taste, pupil dilation, positive feeling, euphoria, feelings of contentedness, 
increased heart rate, shortness of breath, increased body temperature, 
detachment from reality, increased perspiration, and clearer thinking. 
e. Evidence of harm from user reports: 'when I took it, I got no high out of it ( or 
not much of one), but felt very empty, depressed, and hopeless for like 4 
hours after taking only ~25mg'(Bluelight.ru), negative mood, feelings of 
emptiness, depression, hopelessness, insomnia, user overdose reported. 
(Bluelight.ru): heart palpitations, high heart rate, and blood pressure. 
Methiopropamine 
a. Effects classification: Phenethylamine - amphetamine 
b. Chemical Name: N-methyl-1-(thiophen-2-yl)propan-2-amine 
c. Description: Methamphetamine analogue 
d. User reported psychological and physiological effects: mild euphoria, 
increased alertness, increased energy levels, increased sexual arousal, 
increased heart rate, and loss of appetite (Erowid.org). 
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e. Evidence of harm from user reports: psychological dependency, 
vasoconstriction, anxiety, difficulty urinating, laboured breathing, increased 
heart rate, chest tightness, hangover effects (nausea, headache, dizziness, lack 
of energy), and hallucinations ( with prolonged use). 
f. Abuse/dependence risk: 'I snorted one and sat down to wait. The drip was not 
unpleasant and I soon felt very stimulated. However, I had this inkling that 
perhaps a bit of euphoria was coming my way, so I had another line. The 
second line gave me a good kick so I had another ... I think you get where this 
is going. Pretty soon I was measuring out another batch of lines, 30mg this 
time' ... This went on to the third day. That night I began experiencing chest 
pains and headache. However, the thrill of it all was so compelling that I 
continued to use despite my growing fear that I was going to have a heart 
attack. I started hallucinating too ... The cravings continued for about a 
week .. .I remember being very impulsive ... Conclusion? This really has all 
the negatives of crystal meth, 4MMC, and MDPV etc ... I really think this is 
bad stuff: it makes you careless, it is potentially toxic, and most certainly 
addictive; Bluelight.ru: User 'Midinoz': 'had to fight off the urge to redose 
(which was very strong, akin to mephedrone). 
5-MeO-DALT 
a. Effects classification: Psychedelic tryptamine 
b. Chemical Name: N-diallyl-5-methoxytryptamine 
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c. User reported psychological and physiological effects: lightheadedness, 
warmth, tight chest, heavy breathing, disorientation, 'good feeling', clammy 
skin, hallucination, perspiration, dissociation, changes in colour and pattern 
perception (becomes more vivid), euphoria, increased heart rate, altered 
perception ofreality, 'like emerging from a dream ... over and over', tingling 
sensations, malaise, confusion, ataxia (Experience 92110), loss of orientation 
- time and location, visual hallucination, leg and body temor/twitches, bodily 
euphoria, and increased energy levels. 
d. Evidence of harm from user reports: 'negative trip', panic attack, anxiety, 
suicidal ideation, loss of control (seen in a negative light by users), chest 
pains, convulsions, and seizures ( during suspected overdose). 
Flephedrone 
0 
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a. Effects classification: Cathinone, stimulant, euphoriant 
b. Chemical Name: 4-fluoromethcathinone 
c. Description: Empathogenic effects - short history of human consumption 
d. User reported psychological and physiological effects: stimulation - both 
mental and physical, euphoria, heightened mood, empathy, increased 
sociability, increased desire to talk, increased concentration, increased 
motivation, change in consciousness, decreased appetite, dilated pupils, 
bodily sensations ( flushing in the face, chills, goosebumps), deregulation of 
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body temperature, increased perspiration, increased heart rate, heightened 
blood pressure, nystagmus, and tremors. 
e. Evidence of harm from user reports: uncomfortable bodily temperature 
changes, (sweating/chill), heart palpitations, impaired short term memory, 
tension in jaws (grinding teeth), muscle tension and pain, dizziness, vertigo, 
feelings of lightheadedness, headache, nausea, and numbness. 
f. Abuse/dependence risk: increased desire to redose, craving for initial 
euphoric effects - 'compulsive use patterns' have been reported. Some 
evidence of psychological addiction. 
4-MEC 
a. Effects classification: Stimulant, entactogen-phenethylamine, amphetamine 
and cathinone classes 
b. Chemical Name: 4-Methyethcathinone 
c. Description: Similarities to mephedrone 
d. User reported psychological and physiological effects: euphoria, detachment 
from reality, relaxation, dissociation, empathy toward others 
e. Evidence of harm from user reports: tachycardia, bingeing, 'emotional crash', 
feelings of depression, and hangover effects. 
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f. Abuse/dependence risk: Evidence of strong urge to redose, tolerance to 
effects following redosing, cravings for the drug, and loss of control over 
levels of use. 
MDPV 
0 0 0 
< 0 
a. Effects classification: Stimulant 
b. Chemical Name: 3,4-Methylenedioxypyrovalerone 
c. Description: Acts as a norepinephrine-dopamine reuptake inhibitor, is known 
for tendency to induce 'compulsive redosing' (Erowid) 
d. User reported psychological and physiological effects: Euphoria, 
talkativeness, increased focus, and increased alertness. 
e. Evidence of harm from user reports: feelings of depression when not taking 
the substance, some reported anxiety, insomnia following use, impulsivity, 
paranoia, visual and auditory hallucinations, short term memory loss, loss of 
balance, nausea, inability to breathe, heightened blood pressure, tense 
muscles, irregular heartbeat, perspiration, stomach cramps, hospitalisation 
due to impulsivity/loss of control, and kidney failure. 
f. Paranoia and hallucinations: 'I thought campus police was outside my house, 
attempting to arrest me. I thought friends and loved ones were plotting 
against me. I was hearing sirens and fog horns constantly, from multiple 
directions. I heard voices of my friends talking shit about me. I thought my 
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hair was falling out and bugs were crawling on me. Basically I was in hell' 
(Erowid.org, 2011 ). 
g. Abuse/dependence: tolerance, cravings, users report 'being addicted', some 
users report daily use - mostly caused by desire to continuously redose, 
10 users reported suffering from tolerance, and craving for the drug, with 
some describing the drug as 'addictive'. 
Butylone 
0 
< 0 
a. Effects classification: Entactogen, psychedelic, stimulant - phenethylamine 
b. Chemical Name: ~-keto-N-methylbenzodioxolylbutanamine 
c. Description: Metabolised in a similar way to methylone, similar effects to 
MDMA (Erowid). 
d. User reported psychological and physiological effects: alertness, feelings of 
openness, loss of motivation, euphoria, cycle between energy, and loss of 
motivation. 
e. Evidence of harm from user reports: stomach pain on comedown, depression 
after use of drug, and headaches. 
DMAA 
a. Effects classification: Stimulant 
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b. Chemical Name: Methylhexanamine; 1,3-dimethylamylamine 
c. Description: Known as a dietary supplement 
d. User reported psychological and physiological effects: increased energy, 
'adrenaline like' high. 
e. Evidence of harm from user reports: high blood pressure, headaches, and 
vomiting. 
f. Has been banned by the Therapeutic Goods Administration in Australia. 
Methylone 
<o 
0 
a. Effects classification: Euphoric empathogen - phenethylamine class 
b. Chemical Name: 3,4-methylenedioxymethcathinone 
c. Description: Synthetic empathogen 
d. User reported psychological and physiological effects: heightened mood, 
wellbeing, positive feelings, increased desire to communicate, enhanced 
awareness/perception, altered perception/consciousness, euphoria, dilated 
pupils, decreased focus/concentration, restlessness, change in perception of 
time, increased body temperature, increase in heart rate, and loss of appetite. 
e. Evidence of harm from user reports: Muscle tension, ache - tension in jaw, 
perspiration, nausea, vomiting, dizziness, confusion, paranoia, fear, racing 
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heart and heart palpitations, inhibited circulation, vasoconstriction, headache, 
and depression. 
f. Abuse/dependence risk: reported by three users (Erowid.org): reported 
tolerance, craving for other substances - alcohol and benzodiazepines, 
increased use/substitution for other substances, loss of motivation - taking for 
granted responsibilities, andbinging (re-dosing for up to 12 hours) . 
Preliminary Discussion 
Study 2 
A vast number of chemicals were identified as being available to Australian 
consumers using the pilot internet monitoring system. The top ten identified 
substances were then researched, with details of their chemical structure, user 
reported psychological and physical effects, and user reported evidence of harm 
collated. In the top 10 substances identified, the question remains as to how 
widespread their use is in Australia. Although they are available, the EDRS (2010) 
and other national surveys report that they are used (minimally)by Regular Ecstasy 
Users. 
MDPV has been associated with significant harm. From a research 
perspective, the fact that this drug has been identified as one of the most likely to be 
available to Australian consumers, is concerning. The narrative review was able to 
identify that this substance has been associated with physical and psychological harm 
(including depression, anxiety, paranoia, visual/auditory hallucinations and substance 
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abuse and dependence), a finding that is prevalent in the research literature (Borek & 
Holstege, 2012; Durham, 2011; Murray, Murphy & Beuhler, 2012; Ross, Watson & 
Goldberger, 2011; Thornton, Gerona, & Tomaszewski, 2012). The 
rewarding/reinforcing effect of this substance in particular has been confirmed by 
Watterson and colleagues (2012) and Baumann and colleagues (2012). MDPV was 
found to have similar rates of drug use escalation as methamphetamine, a known 
substance of abuse, with what the authors describe as reinforcing properties, and high 
potential for abuse and addiction (Watterson et al.). From a clinical perspective, this 
suggests that it is not only a potentially addictive substance, (with little research data 
available about it), but is also available in Australia, and has the added potential to be 
a substance of abuse, that will likely be encountered in clinical settings. 
The data available on the prevalence of use of EPS in Australia is relatively 
limited. However, law enforcement agencies have seized such substances from 
traditional storefronts and internet sources (ACaBP, 2012; Chamberlin, 2012).Use of 
these drugs has been reported in the US, with shipments seized by customs 
confirming the presence of substances such as MDPV, methylone, and mephedrone 
through chemical analyses (Spiller, Ryan, Weston & Jansen, 2011). Furthermore, the 
presence of MDPV has been confirmed in 'blends' found in Australia (Chamberlin, 
2012). 
The user reports identified in the narrative review of the top 10 drugs have 
various limitations. Firstly, they contain fairly subjective accounts from users about 
their experience of the substance. The amount of substance consumed by each 
individual may vary in terms of purity. The exact consumption amounts cannot be 
easily verified, and of course, there are ethical concerns with subjecting human 
participants to 'testing' of these substances with very little information pertaining to 
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their safety. Further to this, the question of whether these reports are idiosyncratic 
and subject to variation, depending on the users familiarity or exposure to these and 
other substances, requires greater research. Although this narrative review can 
provide some insight into the physical, psychological harm, and the potential for user 
abuse and dependence, it has major limitations in terms of its capacity to legitimately 
verify the actual chemicals being consumed by users. 
Discussion 
The current study aimed to pilot an internet monitoring system, in order to discover 
what EPS are becoming available to the Australian public. The internet monitoring 
system, whilst able to identify a diverse range of internet vendors and products, has 
some major limitations. Firstly, the search terms used over time needed to be 
reviewed, in order to maintain their relevance and capacity to encapsulate the 
dynamic and ever changing chemicals that are becoming available to consumers. 
Secondly, the system fails to capture the EPS that may be available through 
traditional shop fronts and other internet vendors. 
The second aim of the study was to research and catalogue information based 
on the ten most prevalently advertised for sale EPS in Australia. The purpose of 
which was to document the effects of these drugs, (based on user reports), in terms of 
their, psychological, and physical effects. The top ten drugs were identified and 
documented, with user reports examined and reviewed to be summarised in terms of 
their physical/psychological effects and user reports of abuse or dependence. Some 
of these drugs, although not all, were associated with harm (psychological) with 
some users reporting experience of tolerance to the drug and craving for more of the 
substance. One drug in particular, MDPV, which was identified as being available to 
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Australian consumers through the internet monitoring system, has been shown to be 
associated with both physical and psychological harm, by sources other than user 
reports (Baumann, et al., 2012; Borek & Holstege, 2012; Durham, 2011; Murray, 
Murphy & Beuhler, 2012; Ross, Watson & Goldberger, 2011; Thornton, Gerona, & 
Tomaszewski, 2012; Watterson et al., 2012). 
The current study has wide ranging implications for the mental health 
community, law enforcement agencies and governing bodies. Not only does the 
study highlight the dynamic and ever changing nature of drug use, generally, it 
shows that the Australian public will at some point encounter EPS of which they may 
have limited or no information about. The identified EPS have been shown to be 
associated with severe physical harms, hospitalisation, hallucinations, psychosis and 
even death. Individuals who may use these substances for recreational purposes may 
take doses at levels which they did not expect, resulting in quite severe 
consequences. For clinical psychologists, some substances such as MDPV may 
become a new drug of dependence, and may result in increasing presentations for 
psychological interventions. The current research could benefit greatly from some 
adjustment in terms of search terms used and more complete investigation into the 
diverse retailers distributing EPS within Australia. Furthermore, more experimental 
and evidence-based research is required to better inform health professionals and 
governing bodies about the potential for harm and abuse of these substances, in order 
to inform harm-minimisation and also to deal with presentations of individuals who 
may have been exposed to these drugs. 
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